In Vivo Nonclinical Evaluation of Activity and Safety of a T Cell Receptor Engineered Regulatory T Cell Therapy for MS Progression Independent of Relapse Activity
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
